Case-studies show darunavir does not protect against CoV-2
Although in vitro studies reported possible antiviral activity of boosted darunavir (DRV) against CoV-2, in March 2020 Janssen issued an early statement advising against using this drug in research against COVID 19. 
Nevertheless, and to confirm lack of protection, three cases have been reported of HIV positive people (two men and one woman) who were diagnosed with COVID-19 despite using boosted-darunavir-based ART. 
The historical details of the three cases are not worth reporting, as the approach to management is already out of date and against current guidelines (ie – switching DRV to lopinavir/r and adding hydroxychloroquine).
- Janssen press statement. Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2. (16 March 2020).
- Riva D et al. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacological Research (157), 104826 (20 April 2020).